Patent Application
20170072393
The present application pertains to the field of biological material collection and storage. More particularly, the present application relates to a device for collecting, transporting and storing biomolecules from a biological sample, such as feces.
There are various means and devices which have been developed for the collection, transport and analysis of biological samples. Many such samples are fecal samples obtained from humans or other mammalian species. Feces is a useful, non-invasive sample type that can be used for several biological examinations such as parasite screening and fecal occult blood testing (FOBT); both of which are used for the diagnosis of acute gastrointestinal (GI) pathology. There is mounting scientific evidence, however, suggesting that examination of the nucleic acid within the microbial community of the human GI tract can provide insights into both the onset and progression of several human diseases and disorders. These range from obesity and other metabolic disorders (Korecka & Arulampalam 2012) to neurological pathologies (Culligan et al. 2013) and colorectal cancer (CRC, Cole et al. 2003; Osborne et al. 2012).
Human infants are born virtually free of intestinal microbiota, despite the presence of various microorganisms in the amniotic fluid (DiGiulio et al. 2008). The first fecal samples produced by infants following birth are low in microbial density (Palmer et al. 2007). The microbes present in the gut of infants is unstable for the first one to three years of life, after which time the diversity of species begins to resemble that seen in an adult GI tract (Kostic et al. 2013; Palmer et al. 2007), when the intestinal lumen is populated by trillions of microbiota. Over the past century, and in particular within the last two decades, it has become increasingly evident that the microbes within the human GI are required for a wide variety of processes essential for human health (Evans et al. 2013; Korecka & Arulampalam 2012). For example, one of the major contributions of the gut microbiota to humans is the production of short-chain fatty acids, which is a significant source of energy (Evans et al. 2013). Thus, the acquisition of gut microbes is an essential part of normal development (Kostic et al. 2013). In order to elucidate both the identity and the specific roles of the microbial species present in the GI tract, much of the research has focused on metagenomic analysis (the assessment of the total genetic material (DNA and RNA)) of the pool of microbiota present. The metagenome of the microbiota is commonly referred to as the microbiome.
The first step in metagenomic analysis is the acquisition of a sample which is representative of the whole environment of microbes and which allows isolation of total metagenomic DNA/RNA. The methods and devices used to collect and later transport fecal samples should therefore provide a consistent, measurable sample, preserve the diverse profile of organisms represented by the microbiome, and minimize the risk of contamination for the user.
In the current standard of practice, a small tub or similar vessel is used by the donor to collect the entire fecal sample; this same vessel is used for storage and transport. In order to preserve the sample, and by extension the microbiota and the microbiome, the entire sample within this container, is packed into a larger box and kept frozen on dry ice (−78° C.) during storage and transport to a central facility prior to isolation of nucleic acids. While the collection of the sample is straightforward from the perspective of the donor, maintaining these samples frozen from the point of collection is understandably inconvenient and potentially cost-prohibitive for the researcher. Additionally, from the perspective of the researcher, obtaining a secondary consistently sized sample from these collections requires thawing and a potentially messy or distasteful transfer step. A collection device and/or method which removes the necessity for frozen storage and allows for quantitative sampling and simplified postal transport, while maintaining the ease of use for the donor would thus be a marked improvement in the field.
It is important to note that more cost-effective methods such as collecting with a brush/swab or transferring to a smaller container may not only be unsuitable for collecting samples of suitable quality for use in metagenomic analysis of the microbiota, it may also add unwanted complexity for both the donor and the researcher. Due to the necessarily private nature of the production of fecal matter, the collection of such samples is typically performed by the donor, who is likely unfamiliar with the particulars of proper specimen collection.
Moreover, the unpleasant aspects of feces (in particular the odor and the potential for transmission of infectious organisms) often results in reluctance or inability to handle the sample. Even in the context of early diagnosis of potentially fatal diseases such as CRC, participation in fecal donation can be quite low, especially if complex steps are required (Cole et al. 2003; Osborne et al. 2012).
In order to overcome some of these difficulties, several devices and methods have been described for the collection and transport of feces. Many of these are specifically intended to facilitate parasite screening or FOBT, the features of which typically preclude use in metagenomic analysis of fecal microbiota. For example, in parasite screening, the aim is to strain the fecal matter (and ultimately discard it) in order to retain and examine any eggs, larvae, or adult parasites (typically intestinal worms) which may be present. In terms of FOBT, a common test used in CRC screening, the Guaiac Dye Test (e.g. Hemoccult®) relies on a smear of feces applied to a paper pad and allowed to dry in air. The lower GI of humans is populated mainly by Bacteroides and Firmicutes, microbial families comprised mainly of obligate anaerobic species (Korecka & Arulampalam 2012 for which sustained exposure to oxygen is toxic. Thus fecal samples collected by this method cannot provide an accurate representation of the microbiome.
Several fecal collection/transport systems which do not have the aforementioned disadvantages involve a main tube and stick-like collector or spoon (which may or may not be integrated into a cap) and a liquid contained in the main tube. One such collection device described in U.S. Pat. No. 8,556,826 relies on a fecal specimen collector with delicate, brush- or stick-like features. In order to obtain a sample, the fecal specimen collector is inserted into the fecal sample, permitting the fecal matter to adhere to the fine features of the collector. The collector is then inserted into the main tube portion (bottle body) which contains a diluent liquid. The user seals the top cover onto the bottle body and shakes the bottle body to mix the sample with the diluent liquid prior to accessing the feces-diluent mixture. While this invention allows for the collection of a smaller fecal sample, the intended use is the microscopic observation of the diluted feces sample or examination by test paper. The invention does not allow for the collection of a quantitatively uniform fecal sample size, a feature that would allow for more reliable comparison of data.
Further, fecal samples can be highly variable both within and between individuals, ranging from hard pellet-like droplets (Type 1), to a soft semi-solid (Type 4) or to completely fluid (Type 7) (so-called “Bristol scale”, Heaton et al. 1992; Lewis & Heaton 1997). The brush/stick-like features may limit the ability to collect harder more pellet-like samples, and the reliance on fluid turbulence alone to effect mixing may lead to inefficient disruption and ultimately non-homogeneous samples. Moreover, role of the liquid in this case is to dilute the sample only, and not to preserve biomolecules, such as DNA and RNA. This is a significant limitation due to the fact that sample collection approaches can have a large impact on the microbiome, and measurable metagenomic differences can be observed in as little as 20 minutes (Couch et al. 2013). It is critical in studying the microbiome, that an accurate “snapshot” of the microbiota present at the time of collection is obtained.
A second type of fecal sample collector described in U.S. Pat. No. 8,623,665, teaches a system comprising a container, a collector (with an optional snap-on filter) and a cap. The user first collects the fecal sample with the collector (which may be shaped like a spoon, swab, fork, etc.), attaches the filter if being used, and finally the sample and collector are inserted into the container and the container is closed with the cap before being sent to the testing facility, where a processing fluid is added. By transporting the fecal sample to the processing facility before introducing a processing fluid, the integrity of the sample may be compromised as described above. Further, with respect to Type 1 samples, there is also the risk of desiccation in the container prior to processing which may make disruption of the sample with the processing fluid difficult, a step which is necessary to ensure that the entire sample (and the associated metagenome) is available for analysis.
Again in this example, it is not possible to reproducibly collect a sample of a defined amount, nor is there a means of preservation. An additional complication is the transport of the sample in the container, which is secured with a snap closure. Such a closure may pose no problem with harder more pellet-like (Type 1) samples; however there is a considerable risk of leakage with Type 5-7 samples. The consequence of which is contamination of the outside of the collection container and the possible spread of infection.
In light of the previous examples, it becomes clear that there is a necessity for a device and method that will allow the reproducible collection of a defined amount of biological sample in order to carry out analyses of biomolecules. The present invention addresses these issues and also facilitates the rapid and complete disruption and subsequent homogenization of the sample with a preserving means, while providing leak-proof transport and storage. Additionally, according to the invention, the collection of the sample can be carried out in a manner that is convenient and easy for the donor to perform in private without risk of contamination. Finally, the method and device delivers a high quality, stable sample which is easily transported in a cost-effective manner.
This background information is provided for the purpose of making known information believed by the applicant to be of possible relevance to the present invention. No admission is necessarily intended, nor should be construed, that any of the preceding information constitutes prior art against the present invention.
An object of the present invention is to provide an improved biomolecule collection, storage and preservation device, particularly for the collection of nucleic acids from samples, such as feces.
In accordance with an aspect of the present invention, there is provided a sample receiving device comprising a vial, a receptacle in communication with the vial for receiving the sample, and a cap comprising a pusher, the pusher for engaging with the sample in the receptacle, wherein the receptacle comprises a disrupting member for disrupting the sample when the pusher engages with the sample in the receptacle and expels the disrupted sample into the vial.
The receptacle can be a volumetric disruptor, which holds a particular volume or mass of sample, such as a biological sample, therein. The biological sample can be any suitable biological sample, but in particular can be a fecal sample, derived from an animal, such as a mammal including a human. In certain embodiments, the receptacle can hold between about 200 mg to 2 g, or about 400 mg of sample, particularly when feces is used.
In certain embodiments, the pusher comprises a first end connected to an inner portion of the cap, and a second end for engaging the sample and, for example, an inner wall of the receptacle. The pusher may be concave and comprises a lip and a lower end surface. The pusher expels the sample through the disrupting member of the receptacle and into the vial.
In certain embodiments, the vial further comprises a mixing means, such as one or more balls (including one or more ball bearings, for example), which can be used to homogenize the sample. The vial can further comprise a composition for preserving the biomolecule. Exemplary compositions that can be used are described in applicant's U.S. patent application Ser. No. 61/949,692, filed Mar. 7, 2014, the entire contents of which are hereby incorporated by reference. In certain embodiments, the biomolecule is a nucleic acid.
The present application also provides a receptacle for receiving a biological sample comprising a first open end for receiving the sample, a second end for engaging with a vial, and a disrupting member for disrupting the sample when the sample is placed on the disrupting member. The disrupting member can comprise one or more openings therethrough for passage of the sample into the vial and disrupting projections for disrupting the sample as the sample passes through the disruptor. In certain embodiments, the disrupting member can take any shape suitable for disrupting the sample, but can include circular, cross-shaped or clover leaf-shaped openings, for example.
The receptacle can comprise a thread for engaging a cap and/or for engaging the vial. Typically, the vial and/or the cap have complementary threads which permit the receptacle to attach and secure to the vial and/or cap. In certain embodiments, the receptacle is convex. This facilitates engagement with certain caps that comprise concave pushers as described herein.
In accordance with another aspect of the present invention there is provided a method of preserving a biomolecule in a biological sample, the method comprising: a) obtaining a sample; b) obtaining a device as described herein; c) removing the cap from the receptacle attached to the vial; d) placing the sample in the receptacle; e) placing the cap over the receptacle; f) securing the cap with the receptacle, thereby engaging the pusher with the receptacle and engaging the sample with the disrupting means to expel the sample into the vial; and g) mixing the expelled sample with a composition in the vial for preserving the biomolecule within the sample. The mixing step can further comprise homogenizing the expelled sample with a mixing means, such as a metal ball bearing.
In accordance with another aspect of the present application, there is provided a system for preserving a biomolecule from a sample, the system comprising: a vial, a receptacle for receiving the sample in communication with the vial, a cap comprising a pusher, the pusher for engaging with the sample in the receptacle, wherein the receptacle comprises a disrupting member for disrupting the sample when the pusher engages with the sample in the receptacle for expulsion of the sample into the vial, a mixing means such as a ball bearing for further homogenizing the sample once expelled from the receptacle into the vial, and a composition in the vial for preserving the biomolecule in the disrupted expelled sample.
In accordance with another aspect of the present application there is provided a kit comprising the device as described herein, and instructions for use in preserving a biomolecule from a biological sample. In particular embodiments, the sample is a fecal sample and the biomolecule is a nucleic acid.
For a better understanding of the present invention, as well as other aspects and further features thereof, reference is made to the following description which is to be used in conjunction with the accompanying drawings, where:
The present application provides a sample receiving device designed to facilitate convenient collection, storage and transportation of biological samples, such as feces. The device is particularly advantageous in that it permits a user to collect a desired quantity of sample and to preserve and store biomolecules contained therein. Optionally, the device can be used with a composition for preserving and stabilizing the biomolecule therein, such as nucleic acids.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
The term “comprising” as used herein will be understood to mean that the list following is non-exhaustive and may or may not include any other additional suitable items, for example one or more further feature(s), component(s) and/or ingredient(s) as appropriate.
As used herein, a “biomolecule” includes biological molecules and can include molecules such as nucleic acids or proteins, for example.
As used herein, a “biological sample” is any specimen that potentially contains a substance of interest, in particular a nucleic acid, and optionally a protein or other biomolecules of interest. The term “sample” can encompass a solution, such as an aqueous solution, cell, tissue, biopsy, powder, or population of one or more of the same. The sample can be a biological sample, such as saliva, sputum, buccal swab sample, serum, plasma, blood, buffy coat, pharyngeal, nasal/nasal pharyngeal or sinus swabs or secretions, throat swabs or scrapings, urine, mucous, feces/stool/excrement, rectal swabs, lesion swabs, chyme, vomit, gastric juices, pancreatic juices, gastrointestinal (GI) tract fluids or solids, semen/sperm, urethral swabs and secretions, cerebral spinal fluid, products of lactation or menstruation, egg yolk, amniotic fluid, aqueous humour, vitreous humour, cervical secretions or swabs, vaginal fluid/secretions/swabs or scrapings, bone marrow samples and aspirates, pleural fluid and effusions, sweat, pus, tears, lymph, bronchial or lung lavage or aspirates, peritoneal effusions, cell cultures and cell suspensions, bacteria, virus, fungus, connective tissue, epithelium, epithelial swabs and smears, mucosal membrane, muscle tissue, placental tissue, biopsies, exudates, organ tissue, nerve tissue, hair, skin, or nails, wherein samples of the foregoing may be obtained from for example, a vertebrate, including a mammal. A mammal can be, for example, a human, a non-human primate, cattle (such as cow, goat, or sheep), as well as a dog, cat, horse, etc. The sample can also include soil, effluent, or wastewater, to collect from microorganisms therein.
In one embodiment, the biological sample is a fecal sample and the subject is a mammal. In another embodiment, the biological sample is a fecal sample and the subject is a human.
As used herein, a “fecal sample” refers to a waste product from an animal's digestive tract expelled through the anus or cloaca during defecation. In the case of human feces, the fecal matter can be represented by any of the seven types of stool in the Bristol stool scale.
As used herein, a nucleic acid can be DNA or RNA, including mRNA or viral RNA.
In one embodiment, the nucleic acid is DNA, which can be of human, viral or microbial origin. In another embodiment, the nucleic acid is RNA, which can be of human, viral, fungal, or bacterial origin.
As used herein, a “nucleic acid-preserving composition” or “biomolecule-preserving composition” refers to any suitable composition for preserving and stabilizing a biomolecule, such as a nucleic acid, in a sample, such as a fecal sample, for example. Exemplary compositions that can be used are described in applicant's U.S. patent application Ser. No. 61/949,692, filed Mar. 7, 2014, the entire contents of which are hereby incorporated by reference.
When referring to a nucleic acid, by “stable” is meant that at least about 50% of the initial amount of high molecular weight nucleic acid contained an a sample is still present after storing the sample at room temperature (i.e., 15° C. to 25° C.) for a particular time period.
The device as presented herein comprises a collection vial or tube, a receptacle, and a cap. Optionally, the device can also comprise a mixing means, such as one or more balls (e.g., metal ball bearings). The receptacle is referred to herein as a volumetric disruptor, since it is capable of holding a particular quantity of sample for disruption thereof. The present invention further provides a sample collection system that comprises the device plus additional components. For example, the system can comprise a tool for transferring biological sample to the volumetric disruptor of the device. In addition, the system can comprise a syringe that substitutes for the pusher and that is attachable to the receptacle. This can be used instead of, or in addition to, the cap for adding a sample to the receptacle and, ultimately, the collection vial or tube. The component parts of the sample collection device and system are described below with reference to the figures.
Vial
The sample is collected in a vial or tube, an example of which is shown in
Referring to
In certain embodiments, the exterior surface of the lip of the open end can be grooved or barbed as best shown in
As shown in
The exterior surface 20 of the tube should ideally be transparent or translucent to permit viewing of the sample once collected. The exterior surface 20 can be free of any indicia or other markings, and should be suitable to be comfortably handled by the user.
However, it may be adorned, if desired, and/or have a grip or a raised texture to facilitate handling, or with graduated markings to indicate volume.
As mentioned above, and if desired, a mixing means such as one or more ball bearing(s) can be used. Shown best in
Should the homogenization means/ball be too small with respect to the tube, sample passes around the homogenization means/ball without being dispersed in the stabilizing solution. In contrast, should the homogenization means/ball be too large (e.g., >11.1 mm) with respect to the tube (e.g., 12.9 mm internal diameter), sample is not dispersed or ‘crushed’ between the homogenization means/ball and the walls of the tube, the homogenization means/ball does not gain sufficient momentum, and sample becomes compacted at one or both ends of the tube. Ideally, when the outside diameter of the homogenization means (e.g. 7.9 mm tungsten carbide or stainless steel ball) just clears the inner vertical walls of the tube (e.g. 10 mL tube having internal diameter of 12.9 mm, above) by about 5 mm (2.5 mm on either side of the ball), the homogenization means effectively functions as a homogenizer, rapidly breaking down or disrupting samples, such as a solid and semi-solid feces sample (e.g. 400 mg; Bristol scale type 1-6), collected into a composition (e.g. 2 mL), to form a homogeneous liquid sample which can be readily pipetted or manipulated and processed in the laboratory. This homogenization means ensures the collected biological sample, even solid feces, is rapidly and completely disrupted, and, in doing so, quickly exposed to the stabilization composition. Importantly, it has been found that the density of the homogenization means, not just its diameter, compared to the tube/container, is critical for achieving complete disruption of the sample in a timely manner (20-30 seconds) simply with vigorously shaking the tube by hand. Due to the often sticky, malleable nature of feces (e.g. type 4), complete homogenization of this sample is often difficult to achieve in flat-bottomed or conical-bottomed tubes when utilizing a spherical homogenization means. Hence, a round-bottomed tube for a spherical homogenization means is most ideal.
Surprisingly, for complete homogenization of the harder types of human feces (e.g. 400 mg; Bristol scale type 1-2) in the stabilization composition (e.g. 2 mL), within a reasonable period of time 3 minutes), both the disruption means and the homogenization means are required. In the absence of the volumetric disruptor, the homogenization means alone is not able to rapidly breakdown such hard feces in the composition to form a homogeneous mixture.
In certain embodiments, the exterior base 22 of the tube has a reinforced anti-rotation feature. This is primarily composed of a reinforced “skirt” of extra durable material, such as the plastic used in the remainder of the tube, or any other suitable material.
Cap
As exemplified in
The cap itself can be dimensioned to accommodate the size of an index finger and thumb of a typical user. For example, the cap can be relatively tall to accommodate the width of an adult thumb. This is particularly helpful to reduce any incidence of unscrewing the volumetric disruptor together with the cap, when only removal of the cap is desired. The exterior surface 30 of the cap can be ribbed to facilitate a grip on the cap. Alternatively, and as shown in the embodiment in
The open end 32 of the cap is best shown in
Volumetric Disruptor
The volumetric disruptor is a removable receptacle for receiving a quantity of sample.
The volumetric disruptor is removable from the open end of the tube and is typically used to collect a portion of the sample prior to introducing the sample to the tube. For example, the volumetric disruptor can receive approximately 200 mg to 2 g of sample, such as 400 mg of feces for example, which is suitable for analysis; however, larger or smaller sizes of disruptor may be desired to accommodate different amounts of sample. The disruptor is typically generally hollow and cylindrical or polygonal (such as hexagonal) in shape, for example, such that it complements the shape of the tube and the cap.
In one embodiment shown in
The base end 52 of the volumetric disruptor has a cylindrical wall 55 defining an open end which is slightly wider in diameter than the sample receiving end wall 54. The top of the base end 52 forms a ledge 61 from which the cylindrical wall of the sample receiving end extends. When engaged with the cap, the wall of the cap, when placed over the disruptor, aligns flush with the wall of the base end. Further, the open end of the base fits over the tube, thus closing off the open end of the tube. To facilitate this, the interior surface 57 of the base is also threaded to engage the threading on the tube. The interior of the base of the volumetric disruptor can comprise a tall wiper seal 151 to ensure sealing of the inner wall of the tube thereto. This is particularly advantageous for shipping of the sample and stabilizing composition to ensure a tight seal of the tube with the cap.
The wall of the base 55 can have an indicator, such as a flat surface amongst grooves in the wall, to align with a similar indicator on the cap; once aligned, the complementary indicia indicate proper closure of the cap. The wall can also be made of a transparent or translucent material, if desired, to facilitate viewing of the sample and whether it has been properly loaded in the volumetric disruptor.
As shown in
The disrupting member is ideally rounded and convex. This permits the disrupting member to cooperate by fitting into the concave dimension of the pusher 36. With a sample in the reservoir of the volumetric disruptor, it is ideal for the cap to contact the sample nearest the wall first. This forces the fecal matter towards the centre of the disrupting member and therethrough. This prevents a scenario whereby if the pusher was convex and comprising a “dome”, the dome of the pusher would contact the sample first and force the sample out towards the wall of the volumetric disruptor and out of the reservoir. With the pusher contacting the wall of the volumetric disruptor first, it permits scraping of the wall of sample and force the sample into the disrupting member (and eventually into the tube therebeneath). Also, the structure of the pusher 36 and the reservoir of the volumetric disruptor create a seal as the sample is forced through the disrupting member and into the tube. The pusher forces from the outside in and the scraping of the wall creates a relatively cleaner seal. Additionally, a seal is created on the base and sidewalls of the pusher on the volumetric disruptor. Finally, when the pusher engages the bottom of the disrupting member, the shape of the pusher deforms the disrupting member to provide the maximum amount of sample into the tube. When the cap is engaged by the user and the pusher exerts a downward force on the disrupting member, the projections of the disrupting member 60a-d flex inward and downward. This permits the projections to move closer together by entering the spaces (i.e., the “arms” 58a-d separating the projections). As the projections move, the arms 58a-d become smaller, forcing sample through the increasingly narrower openings. For example, if the sample is feces, the sample is made smaller by the action of the pusher, the encroachment of the projections and the narrowing of the arms. This facilitates a more thorough disruption of the sample and promotes homogenization of the sample in the stabilization and preserving composition within the tube.
Similar to the round bottom of the tube, the curved surface 153 (shown best in
In an exemplary use, the tube comprises a ball bearing and composition for preserving nucleic acids in a sample. The volumetric disruptor is attached (e.g., screwed) to the open end of the tube for receiving the sample and finger-tightened to ensure a seal is formed. A sample, such as a fecal sample, is placed within the sample receiving end of the volumetric disruptor. The user can apply the sample with a probe, stick, spoon, swab, tongue depressor, spatula or any other implement. The sample can also be added using an applicator, such as a syringe, as described in Example 2, below.
The sample is placed on top of the disrupting member, level with the upper lip of the wall of the sample receiving end of the volumetric disruptor. Sufficient sample is added to maximize coverage of the disrupting member and to “fill up” the reservoir within the sample receiving end.
Next, the cap is placed over the volumetric disruptor and, where threads are provided, the cap is rotated on to the volumetric disruptor to ensure a tight fit. By this action, the cap presses down on the sample in the sample receiving end of the volumetric disruptor. The force of the cap disrupts the sample as it is pressed through the disrupting member to form pieces of sample that are more readily suspendable in any composition present in the tube. The concave orientation of the interior surface of the cap prevents compaction of the sample within corners of the junction between the pusher and the volumetric disruptor. A tall wipe seal can be used to seal the inner wall of the tube with the volumetric disruptor, as described herein.
The user then vigorously shakes the tube by hand with the cap firmly secured over the volumetric disruptor and the tube. This allows the ball bearing (if present) to engage with the sample to disrupt it further, and to promote complete suspension of the sample in the liquid chemistry within the tube. The user can shake for any desired amount of time, typically for about 30 seconds, until the sample appears to be suitably mixed with the chemistry solution. While not all particles of the sample will dissolve in the chemistry solution, the shaking promotes at least a sizable portion of the sample to become dissociated within the solution.
An applicator, such as shown in
In one example, a sample of feces is obtained. First the plunger is pulled back to a defined distance (indicated by the indentation/restriction in the barrel of the syringe) to create a volumetric empty space in the tip of the syringe; the syringe is pushed into the larger quantity of sample to collect a core sample which fills the empty space created in the last step. Ideally, the bottom end 74 of the syringe tube is of a suitable and desired volume that fits the volume of the volumetric disruptor.
The bottom end 74 of the syringe tube is then placed over the volumetric disruptor. In certain embodiments, the bottom end of the syringe tube is threaded and complements the threads of the volumetric disruptor. The user then presses down on the piston 70 at the first end 78 to expel the sample from the syringe tube 70. Depressing the piston will push the sample out of the syringe and through the disrupting member of the volumetric disruptor, into the tube. In effect, the syringe can function as the pusher as described above. It would be particularly advantageous if the syringe plunger 76 is similarly concave to complement the convex structure of the disrupting member.
For liquid samples (e.g., blood, urine, saliva, cell suspensions), including type 7 feces, pulling back the plunger of the modified syringe will draw-up a known volume of liquid sample which can be expelled into the tube via the volumetric disruptor. Hence, selection of an appropriate applicator enables the volumetric collection of a wide array of sample types ranging from liquid (type 7 feces) to hard solids (type 1 feces).
The sample may then be processed according to standard protocols to isolate, amplify and store nucleic acids from the sample.
All publications, patents and patent applications mentioned in this Specification are indicative of the level of skill of those skilled in the art to which this invention pertains and are herein incorporated by reference to the same extent as if each individual publication, patent, or patent applications was specifically and individually indicated to be incorporated by reference.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims. The scope of the claims should not be limited to the preferred embodiments in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Cole S R, Young G P, Esterman A, Cadd B, Morcom J (2003) A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. Journal of Medical Screening 10:117-122.
Couch R D, Navarro K, Sikaroodi M, Gillevet P, Forsyth C B, Mutlu E, Engen P A, Keshavarzian A (2013) The approach to sample acquisition and its impact on the derived human fecal microbiome and VOC metabolome. PloS One 8(11):e81163.
Culligan E P, Sleator R D, Marchesi J R, Hill C (2013). Metagenomics and novel gene discovery: Promise and potential for novel therapeutics. Virulence 5(3):399-412.
DiGiulio D B, Romero R, Amogan H P, Kusanovic J P, Bik E M, Gotsch F, Kim O, Erez O, Edvin S, Reiman D A (2008) Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PloS One 3(8):e3056.
Evans J M, Morris L S, Marchesi J R (2013) The gut microbiome: the role of a virtual organ in the endocrinology of the host. The Journal of Endocrinology 218(3):R37-47.
Heaton K W, Radvan J, Cripps H, Mountford R A, Braddon F E M, Huges A O (1992) Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 33(6):818-24.
Korecka A, Arulampalam V (2012) The gut microbiome: scourge, sentinel or spectator? Journal of Oral Microbiology 4: 1-14.
Kostic A D, Howitt M R, Garrett W S (2013) Exploring host—microbiota interactions in animal models and humans. Genes and Development 27: 701-718.
Lewis S J, Heaton K W (1997) Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology 32: 920-924.
Osborne J M, Wilson C, Moore V, Gregory T, Flight I, Young GP (2012) Sample preference for colorectal cancer screening tests : Blood or stool ? Open Journal of Preventive Medicine 2(3): 326-331.
Palmer C, Bik E M, DiGiulio DB, Reiman D A, Brown P O (2007) Development of the human infant intestinal microbiota. PLoS Biology 5(7): e177.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CA2015/050434 | 5/13/2015 | WO | 00 |
